These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32022744)

  • 1. Advances in the diagnosis and treatment of latent tuberculosis infection.
    Jung YEG; Schluger NW
    Curr Opin Infect Dis; 2020 Apr; 33(2):166-172. PubMed ID: 32022744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of latent tuberculosis infection.
    Parekh MJ; Schluger NW
    Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Latent Tuberculosis Infection-An Update.
    Huaman MA; Sterling TR
    Clin Chest Med; 2019 Dec; 40(4):839-848. PubMed ID: 31731988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
    McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
    BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Kahwati LC; Feltner C; Halpern M; Woodell CL; Boland E; Amick HR; Weber RP; Jonas DE
    JAMA; 2016 Sep; 316(9):970-83. PubMed ID: 27599332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress on diagnosis and treatment of latent tuberculosis infection.
    Ying C; He C; Xu K; Li Y; Zhang Y; Wu W
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 51(6):691-696. PubMed ID: 36915977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country.
    Dyrhol-Riise AM; Gran G; Wentzel-Larsen T; Blomberg B; Haanshuus CG; Mørkve O
    BMC Infect Dis; 2010 Mar; 10():57. PubMed ID: 20210999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Latent Tuberculosis Infection.
    Haley CA
    Microbiol Spectr; 2017 Apr; 5(2):. PubMed ID: 28409555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(48):1650-3. PubMed ID: 22157884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence.
    Vidal JS; Silva MT; Sanchez MN
    Rev Soc Bras Med Trop; 2015; 48(5):507-13. PubMed ID: 26516958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates in the Treatment of Active and Latent Tuberculosis.
    Haas MK; Belknap RW
    Semin Respir Crit Care Med; 2018 Jun; 39(3):297-309. PubMed ID: 30071545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Quach P; Skidmore B; Moher D; Alvarez GG
    BMC Infect Dis; 2017 Apr; 17(1):265. PubMed ID: 28399802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
    Cui X; Gao L; Cao B
    Int J Infect Dis; 2020 Mar; 92S():S37-S40. PubMed ID: 32114201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data.
    Stockbridge EL; Loethen AD; Annan E; Miller TL
    PLoS One; 2020; 15(12):e0243102. PubMed ID: 33270737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latent tuberculosis infection: Opportunities and challenges.
    Chee CBE; Reves R; Zhang Y; Belknap R
    Respirology; 2018 Oct; 23(10):893-900. PubMed ID: 29901251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial.
    Rangaka MX; Hamada Y; Duong T; Bern H; Calvert J; Francis M; Clarke AL; Ghanouni A; Layton C; Hack V; Owen-Powell E; Surey J; Sanders K; Booth HL; Crook A; Griffiths C; Horne R; Kunst H; Lipman M; Mandelbaum M; White PJ; Zenner D; Abubakar I
    BMJ Open; 2022 Sep; 12(9):e057717. PubMed ID: 36691120
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.